UPDATE: Washington University School of Medicine in St. Louis ended the clinical trial before completion of patient enrollments.
The FDA gave emergency approval for hospitals around the country to use the malaria drugs hydroxychloroquine and chloroquine to treat severe cases of COVID-19. But the treatment strategy remained unproven. Washington University School of Medicine in St. Louis is involved in a range of COVID-19 response research, including investigating the anti-malarial drugs. In April, researchers launched a clinical trial combining the anti-malaria drugs with the antibiotic azithromycin. In May, the National Institutes of Health launched a clinical trial combining hydroxychloroquine with azithromycin. The goal is to determine if the anti-malarial dugs, alone or in combination with the antibiotic, decrease the severity or duration of respiratory symptoms.


Kathleen Berger
Executive Producer, HEC Science & Technology
Subscribe now ➤ [ Ссылка ]

For more great content from the Higher Education Channel check us out at:
Facebook ➤ [ Ссылка ]
Twitter ➤ [ Ссылка ]
Instagram ➤ [ Ссылка ]

свернуть